CellCentric and ZoBio Enter into Partnership
News Jun 21, 2012
ZoBio and CellCentric have announced that the companies are working together to discover lead compounds against CellCentric’s portfolio of epigenetic therapeutic drug targets.
ZoBio will use its proprietary TINS technology to screen its fragment library against targets nominated by CellCentric.
Hit to lead and lead optimization activities will be further supported by ZoBio’s biophysical and medicinal chemistry research services.
Dr. Gregg Siegal, Chief Scientific Officer at ZoBio said “We are clearly happy that CellCentric has chosen ZoBio as a partner in this challenging project. Epigenetics is an exciting, yet challenging, field. We feel that our unique combination of biophysical and biochemical approaches yields significant advantages in developing small molecule inhibitors of these targets with optimal drug-like properties.”
Dr Anthony Brown, Scientific Director at CellCentric, said “The ZoBio TINS technology offers a unique opportunity to identify novel hit matter against our epigenetic drug targets. The interaction with ZoBio will allow us to expand the breath of our hit finding capabilities and will accelerate our on-going drug discovery activities. We are delighted to enter into this agreement to screen against these novel and exciting epigenetic drug targets.”
Duplicate Genes Offer a Explanation for Differences Between the SexesNews
A study in flies has identified the process by duplicating a gene can help resolve genetic sexual conflict.READ MORE
'Click Chemistry' Reactions Could Boost Cancer-Fighting Drug PotencyNews
Researchers at The Scripps Research Institute (TSRI) have developed a quick and easy way to simultaneously modify dozens of drugs or molecules to improve their disease-fighting properties.READ MORE
Inheritance and Cannibalism Shape the Termite Gut MicrobiomeNews
A huge new study has outlined what influences help create the incredibly diverse termite microbiome.READ MORE